Oncological outcomes from trimodality therapy receiving definitive doses of neoadjuvant chemoradiation (≥60 Gy) and factors influencing consideration for surgery in stage III non-small cell lung cancer-Reference-Cited by-同舟云学术

Oncological outcomes from trimodality therapy receiving definitive doses of neoadjuvant chemoradiation (≥60 Gy) and factors influencing consideration for surgery in stage III non-small cell lung cancer

Published:2017-07 Issue:3 Volume:2 Page:259-269
ISSN:2452-1094
Container-title:Advances in Radiation Oncology
language:en
Short-container-title:Advances in Radiation Oncology

Author:

Vyfhuis Melissa A.L.,Bhooshan Neha,Burrows Whitney M.,Turner Michelle,Suntharalingam Mohan,Donahue James,Nichols Elizabeth M.,Feliciano Josephine,Bentzen Søren M.,Badiyan Shahed,Carr Shamus R.,Friedberg Joseph,Simone Charles B.,Edelman Martin J.,Feigenberg Steven J.,Mohindra Pranshu

Publisher

Elsevier BV

Subject

Radiology Nuclear Medicine and imaging,Oncology

Reference27 articles.

1. Cancer statistics, 2016;Siegel;CA Cancer J Clin,2016

2. The IASLC lung cancer staging project: Proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM Classification for lung cancer;Goldstraw;J Thorac Oncol,2016

3. Nodal stage of surgically resected non-small cell lung cancer and its effect on recurrence patterns and overall survival;Varlotto;Int J Radiat Oncol Biol Phys,2015

4. Mediastinal nodal involvement and the prognosis of non-small cell lung cancer;Watanabe;Chest,1991

5. Prognostic significance of metastasis to the highest mediastinal lymph node in nonsmall cell lung cancer;Sakao;Ann Thorac Surg,2006

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Contemporary Strategies: Incorporating Immunotherapy into Stage 3 Non-small Cell Lung Cancer Treatment;Tuberculosis and Respiratory Diseases;2024-07-01

2. Unresectable Stage III NSCLC Can Be Reevaluated for Resectability After Initial Treatment;Journal of Thoracic Oncology;2023-09

3. ASTRO Radiation Therapy Summary of the ASCO Guideline on Management of Stage III Non-Small Cell Lung Cancer;Practical Radiation Oncology;2023-05

4. Trimodality therapy for patients with stage III non-small-cell lung cancer: A comprehensive surveillance, epidemiology, and end results analysis;Cancer Treatment and Research Communications;2022

5. Surgical complications and clinical outcomes after dose-escalated trimodality therapy for non-small cell lung cancer in the era of intensity-modulated radiotherapy;Radiotherapy and Oncology;2021-12